- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03339661
Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T Cells Immunomonitoring. (SPARCKLING)
Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T
Study Overview
Status
Conditions
Detailed Description
The study aim to demonstrate that the expansion of γδ T cells at the end of curative treatment predicts the absence of virological and clinical relapses. This is a pilot study that will be conducted in the transplant center of Bordeaux and Lyon. After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring:
(I) Secondary prophylaxis will not be started in patients with γδ T cell expansion at the end of curative treatment (group 1) (II) Secondary prophylaxis will be initiated in patients who have not γδ T cell expansion and will continue for 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
The primary outcome of this study will be to evaluate the occurrence of virological relapse, assessed by monitoring CMV ADNemia, at one year of a first CMV disease, in kidney transplant patients, with secondary prophylaxis based on the monitoring of γδ T cells.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33000
- Hôpital Pellegrin - CHU de Bordeaux
-
Lyon, France, 69003
- Hôpital Edouard Herriot - Hospices civils de Lyon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female over 18 years old without weight or ethnicity criteria, kidney transplant.
- Patient affiliated or beneficiary of a social security scheme.
- Patient with symptomatic or non-symptomatic CMV infection requiring curative treatment with ganciclovir or valganciclovir.
- Free, informed and written consent signed by the participant and the investigator (at the latest, on the day of inclusion and before any examination required by the research).
Exclusion Criteria:
- Resistance documented to antivirals.
- Hemodialysis patient.
- Number of polymorphonuclear neutrophils less than 500 / μL and / or number of platelets less than 25,000 / μL, and / or lower hemoglobin 8 g / dL.
- Contraindication to valganciclovir, including known hypersensitivity to valganciclovir and / or aciclovir and / or valaciclovir or ganciclovir or their excipients, known severe intolerance to valganciclovir or ganciclovir.
- Women of childbearing age without a negative pregnancy test at baseline and without effective contraception (estrogen-progestin, intrauterine device) throughout the study period and two months after cessation of the follow-up period.
- Nursing women.
- Men without mechanical contraception during treatment and for at least 90 days after treatment.
- Ongoing participation in another clinical trial evaluating a drug. Participation in an observational study will not be considered a contraindication.
- The patient's foreseeable inability to comply with planned visits in the protocol.
- Non-negativation of CMV PCR at 8 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1_ No proph treatment
Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated will depend on medical opinion) during 2 to 8 weeks.
When CMV QNAT becomes regative, if γδ T cell expansion occurs, no secondary prophylaxis treatment will be introduce, and curative treatment stops.
|
After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring.
In this group, expansion of γδ T cell at the end curative treatment was detected, so secondary prophylaxis will not be started.
|
Experimental: Group 2A_Proph treatment and γδ T cells expansion
Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks.
When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum.
The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
|
After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring.
In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum.
The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
|
Experimental: Group 2B_Proph treatment and no γδ T cells expansion
Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks.
When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum.
Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
|
After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring.
In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum.
Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of virological relapse occurence
Time Frame: 12 months after inclusion visit
|
The primary outcome of this study will be to evaluate the occurrence of virological relapse, assessed by monitoring CMV ADNemia.
|
12 months after inclusion visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative incidence of clinical recurrence
Time Frame: 12 months after inclusion visit
|
Cumulative incidence of clinical recurrence defined by a positive CMV PCR associated with clinical and biological signs of CMV disease.
This incidence is expressed as a percentage of the total number of patients with CMV infection included.
|
12 months after inclusion visit
|
γδ T cells expansion dynamic
Time Frame: 12 months after the inclusion visit
|
Description of the dynamics of γδ T cells expansion in all patients.
At each visit, an immunophenotyping with analysis of the percentage of γδ T cells will be performed.
|
12 months after the inclusion visit
|
Cumulative incidence of clinical recurrence at discontinuation of prophylaxis.
Time Frame: 12 months after the inclusion visit
|
These incidences will be expressed as a percentage of the total number of patients who have had CMV infection included.
Recidivism will be collected by the investigating physician when observed during a follow-up visit.
|
12 months after the inclusion visit
|
Cumulative incidence of virological recurrence at discontinuation of prophylaxis.
Time Frame: 12 months after inclusion visit
|
These incidences will be expressed as a percentage of the total number of patients who have had CMV infection included.
Recidivism will be collected by the investigating physician when observed during a follow-up visit.
|
12 months after inclusion visit
|
secondary prophylaxis duration
Time Frame: 12 months after inclusion visit
|
The duration of the secondary prophylaxis is defined by the duration of treatment since the stop of the curative treatment until the stop of the prophylactic treatment.
|
12 months after inclusion visit
|
Prophylaxis treatment savings evaluation
Time Frame: 12 months after inclusion visit
|
Evaluation of prophylaxis treatment savings (compared to a one-month prophylaxis) by number of subject and average total duration (with standard deviation) of treatment.
|
12 months after inclusion visit
|
Proportion of antiviral resistant infections
Time Frame: 12 months after inclusion visit
|
the proportion of antiviral resistant infections confirmed by genotypic analysis (mutations UL97 and UL54) sought during recurrence in case of clinical suspicion.
|
12 months after inclusion visit
|
GFR average
Time Frame: 12 months after inclusion visit
|
GFR average and its standard deviation are estimated according to MDRD formula
|
12 months after inclusion visit
|
Compliance rate
Time Frame: 12 months after inclusion visit
|
The compliance rate will, be performed by a patient notebook.
|
12 months after inclusion visit
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Edouard LHOMME, Dr, USMR
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2016/40
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplant Infection
-
Clinical Hospital MerkurClinical Hospital Centre ZagrebUnknownKidney Transplant Infection | Kidney Transplant RejectionCroatia
-
Singapore General HospitalRecruitingKidney Transplant Infection | Kidney Transplant Rejection | Kidney Transplant; ComplicationsSingapore
-
Hospital de Clinicas de Porto AlegreActive, not recruitingKidney Transplant Infection | Kidney Transplant Rejection | Kidney Transplant Failure | Kidney Transplant Failure and RejectionBrazil
-
Tongji HospitalAnapure BioScience; Caibo MedTech; SKM BioTechRecruitingKidney Transplant Infection | Kidney Transplant Rejection | Immunosuppression | VirusChina
-
Radboud University Medical CenterUniversity of Wisconsin, MadisonRecruitingKidney Transplant Infection | Kidney Transplant; Complications | Kidney Transplant Failure and RejectionNetherlands
-
Vanderbilt University Medical CenterViraCor LaboratoriesActive, not recruitingLiver Transplant Infection | Kidney Transplant Infection | CMV | Heart Transplant InfectionUnited States
-
University Hospital, GrenobleNot yet recruitingCardiovascular Diseases | Kidney Transplant Infection | Immunosuppression | Kidney Transplant; Complications
-
Institute for Clinical and Experimental MedicineNot yet recruitingKidney Transplant InfectionCzechia
-
Maimónides Biomedical Research Institute of CórdobaCompleted
-
University Hospital, RouenNot yet recruiting
Clinical Trials on Group 1_No proph treatment
-
The Affiliated Hospital of Xuzhou Medical UniversityUnknownChronic Kidney Diseases | Mesenchymal Stem Cells | Renal Interstitial FibrosisChina
-
University of California, San DiegoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Tasly Pharmaceutical Group Co., LtdCompleted
-
Baylor College of MedicineCompletedAttention Deficit and Disruptive Behavior Disorders | Attention Deficit Hyperactivity DisorderUnited States
-
Università degli Studi di FerraraCompleted
-
New Mexico VA Healthcare SystemCompletedPost Traumatic Stress DisorderUnited States
-
University Hospital Inselspital, BerneCompletedMultiple SclerosisSwitzerland
-
University of Erlangen-NürnbergFa. Reck MOTOmedCompleted
-
University of MinnesotaCompleted
-
Beijing HuiLongGuan HospitalCompleted